Evoke Pharma (NASDAQ:EVOK) Downgraded by ValuEngine to “Sell”

ValuEngine cut shares of Evoke Pharma (NASDAQ:EVOK) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning, ValuEngine reports.

Other research analysts also recently issued reports about the company. HC Wainwright downgraded Hydrogenics from a buy rating to a neutral rating in a report on Friday, June 28th. Zacks Investment Research downgraded GENEL ENERGY PL/ADR from a buy rating to a hold rating in a report on Tuesday, May 7th.

Shares of EVOK opened at $0.88 on Tuesday. The firm has a market cap of $20.47 million, a P/E ratio of -1.91 and a beta of 1.62. Evoke Pharma has a 12 month low of $0.50 and a 12 month high of $3.40. The stock’s 50-day moving average is $0.66.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.04). As a group, equities analysts predict that Evoke Pharma will post -0.41 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Virtu Financial LLC bought a new position in shares of Evoke Pharma in the 1st quarter worth about $118,000. BlackRock Inc. raised its position in shares of Evoke Pharma by 5.5% in the 4th quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock worth $207,000 after acquiring an additional 4,392 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Evoke Pharma in the 1st quarter worth about $139,000. 7.40% of the stock is owned by hedge funds and other institutional investors.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Featured Story: Futures Contract

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.